ContributorsPublishersAdvertisers

#Esmo

Nursing Times

Peer-to-peer KEYLearning series – Part 3: identifying adverse events

This video series and advertorial are fully funded and developed by MSD. Click the following links for prescribing information for Keytruda® (pembrolizumab):. Licensed indications for Keytruda in metastatic non-small cell lung cancer (NSCLC) are also listed at the end of this advertorial. For UK healthcare professionals only. Peer-to-peer KEYLearning...
CANCER
Picture for Peer-to-peer KEYLearning series – Part 3: identifying adverse events

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

BEVERLY HILLS, Calif., Dec. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the Company's mini-poster presentation abstract is now broadly available on the European Society for Medical Oncology ("ESMO") Immuno-Oncology ("IO") Congress 2021 abstracts webpage. The congress is being held from December 8-11, 2021, in Geneva Switzerland.
MEDICAL & BIOTECH
Picture for GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
TRENDING TOPICS
onclive.com

Notable Treatment Advances in HER2+ MBC

Vijayakrishna Gadi, MD, PhD: I’m going to keep this moving. ESMO [European Society for Medical Oncology Congress 2021] was exciting. There were a lot of neat papers and manuscripts. You know it’s important when The New York Times also picks it up. The public press has also spoken. I’m going to highlight some of these, but I’ll also query with you guys of others you thought were important.
CANCER
onclive.com

ADCs Under Investigation for HER2+ MBC

Volkmar Müller, MD, PhD: With all of these options we have even more coming things, new ADCs [antibody-drug conjugates] apart from trastuzumab deruxtecan. There are 2 things that might be mentioned in this perspective. Dr Traina, can you comment on that?. Tiffany A. Traina, MD: There are additional ADCs in...
SCIENCE
medwirenews.com

ESMO issues recommendations for managing bladder cancer

MedwireNews: A Clinical Practice Guideline for the management of bladder cancer has been developed by ESMO and published in the Annals of Oncology. A multinational and multidisciplinary team of experts contributed to the guideline, which is “based on the latest available scientific data and the authors’ expert opinions.”. The document...
CANCER
StreetInsider.com

Adagene Inc. (ADAG) Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from December 8 to 11, 2021. Both posters are available in the Publications section of the company’s website at www.adagene.com.
MEDICAL & BIOTECH
StreetInsider.com

Bolt Biotherapeutics (BOLT) Reports Positive Interim BDC-1001 Phase 1/2 Data

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the presentation of interim clinical data from the company’s ongoing Phase 1/2 study of BDC-1001, the company’s lead immune-stimulating antibody conjugate (ISAC) in a poster session at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021, being held virtually from Dec. 6-11, 2021. The lead author for the poster is Manish Sharma, M.D., START Midwest, with contributions from Ecaterina Dumbrava, M.D., MD Anderson Cancer Center, and other colleagues from the U.S. and South Korea.
MEDICAL & BIOTECH
cancernetwork.com

Updated Safety Data and Treatment Selection in nmCRPC

Audrey Sternberg: Can you discuss the updated safety data for darolutamide and apalutamide that were presented earlier this year at ASCO [2021 American Society of Clinical Oncology annual meeting] and ESMO [European Society for Medical Oncology Congress 2021]?. Aaron Berger, MD: Yes. It was a longer-term evaluation of the adverse...
SCIENCE
globalsmt.net

esmo Unveils New UniCell Configurations for Production & Testing Processes

Cross-industry Compact Automation Solution Boosts Productivity & Enhances Occupational Safety. — a full-service systems integrator that provides innovative and advanced engineering services —unveils new configurations of UniCell, the company’s cross-industry compact automation housing solution for manufacturers looking to improve productivity levels, production stability, and occupational safety. The UniCell enclosure is...
TECHNOLOGY
medwirenews.com

ESMO malignant pleural mesothelioma guideline published

MedwireNews: ESMO has released a Clinical Practice Guideline to assist physicians in managing people with malignant pleural mesothelioma. The guideline was developed by a panel of multinational experts in accordance with ESMO’s standard operating procedures, and covers topics ranging from diagnosis and staging to treatment and supportive care. With regard...
CANCER
onclive.com

Dr. Pothuri on the Challenges of POLE Testing in Endometrial Cancer

Bhavana Pothuri, MD, discusses the challenges of DNA polymerase epsilon mutation testing in endometrial cancer. Bhavana Pothuri, MD, professor, departments of Obstetrics and Gynecology and Medicine, NYU Grossman School of Medicine, director, Gynecologic Oncology Clinical Trials, NYU Langone Health’s Perlmutter Cancer Center, discusses the challenges of DNA polymerase epsilon (POLE) mutation testing in endometrial cancer.
CANCER

Bolt Biotherapeutics To Present Interim Clinical Data On BDC-1001 Phase 1/2 Clinical Trial At ESMO Immuno-Oncology Congress 2021

REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the company will be presenting interim clinical data in a virtual poster on BDC-1001, starting on December 6, 2021 in conjunction with the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021 taking place on December 8 - 11, 2021. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated to a TLR7/8 agonist with a non-cleavable linker.
MEDICAL & BIOTECH

GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021

BEVERLY HILLS, Calif., Nov. 30, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that an abstract was accepted for presentation at the upcoming European Society for Medical Oncology ("ESMO") Immuno-Oncology ("IO") Congress 2021 to be held December 8-11, 2021 in Geneva Switzerland.
MEDICAL & BIOTECH

Q2 Interim Report - Promising Results Published at ESMO

UPPSALA, SE / ACCESSWIRE / December 1, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Operating profit (loss)-14,314-8,285-26,552-16,950-40,181. Profit (loss) for the period-14,388-8,208-26,613-16,581-39,482. Earnings per share after dilution-0.51-0.29-0.93-0.59-1.39. Significant events during the second quarter. Biovica has strengthened its management team with the addition of Warren Cresswell, President Americas, with responsibility for the launch...
FINANCIAL REPORTS
docwirenews.com

Advances in urologic oncology “OncoUrology Forum Special Edition”: The best of 2020

Actas Urol Esp (Engl Ed). 2021 Nov 26:S2173-5786(21)00143-8. doi: 10.1016/j.acuroe.2021.09.001. Online ahead of print. OBJECTIVE: To provide latest findings of Urologic Oncology on prostate, kidney, and bladder cancer, and analyze its impact on clinical practice as well as future schemes in the medium- and long-term. METHODS: This document reviews the...
CANCER
MENAFN

Novartis presents significant study results during renowned Best of ESMO Conference in Dubai

(MENAFN- Mid-East.Info) Dubai, United Arab Emirates: The Best of ESMO (European Society of Medical Oncology) conference, the leading professional platform for medical oncology for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world, made its way to Dubai earlier this month, on the 5th & 6th of November, as it took place in hybrid format, across the Middle East and Africa region to bring content, knowledge, findings, exploration of the latest medical updates and copyright of the data presented during ESMO at the end of September 2021. With the aim to present the newest data in breast, gastrointestinal, genitourinary and lung cancer, the conference presents the very latest advances in the treatment of cancer and offers an excellent educational program, with a wealth of opportunities for exchange of ideas among delegates. As the event's diamond sponsor, Novartis, a leading global pharmaceutical company, announced its latest significant study findings for Phase III MONALEESA-2, and its overall survival (OS) results during clinical trials.
CANCER
onclive.com

Experts Review Key Data From ESMO Congress 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021. Nearly 2,000 abstracts were included in the proceedings at the European Society for...
CANCER
YOU MAY ALSO LIKE